NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Earnings for NanoViricides, Inc. (NNVC)
Earnings in 2024 (TTM): $-8,294,146
According to NanoViricides, Inc.'s latest financial reports the company's current earnings (TTM) are $-8,294,146. The earnings displayed on this page is the company's Pretax Income.
Earnings history of NanoViricides, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2024 | $-8,294,146 | $-8,294,146 |
| 2023 | $-8,588,573 | $-8,588,573 |
| 2022 | $-8,106,863 | $-8,100,127 |
| 2021 | $-8,822,189 | $-8,907,594 |
| 2020 | $-13,446,538 | $-13,397,539 |
| 2019 | $-8,424,440 | $-8,244,695 |
| 2018 | $-8,563,455 | $-8,563,455 |
| 2017 | $-10,304,490 | $-10,304,490 |
| 2016 | $-10,724,629 | $-10,724,629 |
| 2015 | $-2,198,172 | $-2,198,172 |
| 2014 | $-14,106,474 | $-14,106,474 |
| 2013 | $-8,875,668 | $-8,875,668 |
| 2012 | $-6,207,207 | $-6,207,207 |
| 2011 | $-6,477,165 | $-6,477,165 |
| 2010 | $-4,744,208 | $-4,744,208 |
| 2009 | $-2,787,798,000,000 | $-2,787,798 |
| 2008 | $ | $-2,738,337 |
| 2007 | $ | $-3,118,963 |
| 2006 | $ | $-3,284,432 |
| 2005 | $ | $-66,005 |